CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Trial of JAK Inhibitor Added to Immunotherapy for Treatment of Relapsed/Refractory T-cell Lymphoma and 9p Amplified Lymphomas

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT07283822
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:48.259327+00:00
Published At: 2025-12-16T00:00:00+00:00
Record Updated At: 2025-12-16
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Non-Hodgkin Lymphoma", "Hodgkin Disease Lymphoma", "Non-Hodgkin Lymphoma Refractory/ Relapsed", "Hodgkin Disease Recurrent", "Gray Zone Lymphoma", "Peripheral T-cell Lymphoma", "Cutaneous T-Cell Lymphomas", "Primary Mediastinal B Cell Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-12-16"
protocolSection.identificationModule.nctId: "NCT07283822"
protocolSection.identificationModule.officialTitle: "A Phase II Trial of JAK Inhibitor Added to Immunotherapy for Treatment of Relapsed/Refractory T-cell Lymphoma and 9p Amplified Lymphomas"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.